153 related articles for article (PubMed ID: 18465659)
1. DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders.
Elishmereni M; Bachelet I; Levi-Schaffer F
Curr Opin Investig Drugs; 2008 May; 9(5):491-6. PubMed ID: 18465659
[TBL] [Abstract][Full Text] [Related]
2. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands.
Tahara-Hanaoka S; Miyamoto A; Hara A; Honda S; Shibuya K; Shibuya A
Biochem Biophys Res Commun; 2005 Apr; 329(3):996-1000. PubMed ID: 15752754
[TBL] [Abstract][Full Text] [Related]
4. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
[TBL] [Abstract][Full Text] [Related]
5. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
[TBL] [Abstract][Full Text] [Related]
6. Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.
Xiong P; Sang HW; Zhu M
Immunology; 2015 Nov; 146(3):369-78. PubMed ID: 26235210
[TBL] [Abstract][Full Text] [Related]
7. DNAM-1 and PVR regulate monocyte migration through endothelial junctions.
Reymond N; Imbert AM; Devilard E; Fabre S; Chabannon C; Xerri L; Farnarier C; Cantoni C; Bottino C; Moretta A; Dubreuil P; Lopez M
J Exp Med; 2004 May; 199(10):1331-41. PubMed ID: 15136589
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor.
Shibuya A; Lanier LL; Phillips JH
J Immunol; 1998 Aug; 161(4):1671-6. PubMed ID: 9712030
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of cell adhesion molecule nectin-2/CD112 and its binding to immune receptor DNAM-1/CD226.
Liu J; Qian X; Chen Z; Xu X; Gao F; Zhang S; Zhang R; Qi J; Gao GF; Yan J
J Immunol; 2012 Jun; 188(11):5511-20. PubMed ID: 22547693
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.
Castriconi R; Dondero A; Corrias MV; Lanino E; Pende D; Moretta L; Bottino C; Moretta A
Cancer Res; 2004 Dec; 64(24):9180-4. PubMed ID: 15604290
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.
Deuss FA; Watson GM; Goodall KJ; Leece I; Chatterjee S; Fu Z; Thaysen-Andersen M; Andrews DM; Rossjohn J; Berry R
J Biol Chem; 2019 Aug; 294(33):12534-12546. PubMed ID: 31253644
[TBL] [Abstract][Full Text] [Related]
13. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
[TBL] [Abstract][Full Text] [Related]
15. Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226).
Shirakawa J; Shibuya K; Shibuya A
Int Immunol; 2005 Mar; 17(3):217-23. PubMed ID: 15684041
[TBL] [Abstract][Full Text] [Related]
16. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
18. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.
Tahara-Hanaoka S; Shibuya K; Kai H; Miyamoto A; Morikawa Y; Ohkochi N; Honda S; Shibuya A
Blood; 2006 Feb; 107(4):1491-6. PubMed ID: 16249389
[TBL] [Abstract][Full Text] [Related]
19. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
de Andrade LF; Smyth MJ; Martinet L
Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
[TBL] [Abstract][Full Text] [Related]
20. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.
Stein N; Tsukerman P; Mandelboim O
Hum Antibodies; 2017; 25(3-4):111-119. PubMed ID: 28035916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
